Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee
MWN-AI** Summary
Daxor Corporation (Nasdaq: DXR), a leader in blood volume measurement technology, is enhancing its presence in the outpatient cardiology sector through the launch of a Blood Volume Analysis (BVA) diagnostic program in Oak Ridge, Tennessee. This initiative utilizes Daxor's innovative ezBVA Lab workflow, which allows for a rapid 24-hour turnaround on comprehensive blood volume metrics, significantly aiding cardiology patients' treatment and care management.
According to Daxor CEO Michael Feldschuh, this advancement not only represents a vital expansion into the outpatient space but also emphasizes the importance of accurate volume assessments in managing chronic diseases. With a diagnostic accuracy of 98%, Daxor's technology enables healthcare providers to move beyond estimates, facilitating meaningful, data-driven fluid management. This diagnostic service operates with reimbursement codes and requires no capital investment, making it accessible for healthcare facilities.
Daxor’s goal is to address a critical issue within the healthcare system: the precise measurement of blood volume, which is essential for optimal patient care and management of conditions such as heart failure. With a legacy of over 50 years in innovation, Daxor manufactures the FDA-cleared BVA diagnostic system that offers real-time, precise data helping clinicians make personalized treatment decisions. The company's state-of-the-art manufacturing facility in the U.S. positions it for expedited growth within the market.
As Daxor takes this strategic step forward, it aims to improve patient outcomes and reduce healthcare costs associated with prolonged hospital stays and high readmission rates, demonstrating its commitment to value-based care. For more information about Daxor and its cutting-edge technology, please visit Daxor.com.
MWN-AI** Analysis
Daxor Corporation (Nasdaq: DXR) has recently expanded its presence in the outpatient cardiology market by launching a new Blood Volume Analysis (BVA) diagnostic program in Tennessee. This strategic move positions Daxor to capitalize on the growing demand for accurate diagnostic solutions in patient care, specifically addressing chronic diseases such as heart failure.
One of the critical aspects of Daxor’s expansion is its revolutionary ezBVA Lab, promising a remarkable 98% diagnostic accuracy with a 24-hour turnaround time. This efficiency allows healthcare providers to make swift, data-driven decisions, a crucial factor in managing cardiovascular conditions. The integration of reimbursement codes and the zero capital investment required for employing this technology in outpatient settings further enhances the appeal for medical facilities, promising significant cost savings and improved patient outcomes.
From an investment perspective, Daxor's commitment to improving healthcare efficiency highlights the company's potential to capture a larger market share in the competitive diagnostics sector, especially as cost-effective and precise solutions become paramount in value-based healthcare. The firm's established reputation, extensive experience, and operational readiness—bolstered by its ISO certification and a modern manufacturing facility—position it well for accelerated growth.
However, potential investors should remain cautious. Market uncertainties, the competitive landscape, regulatory hurdles, and the ability to increase physician and market acceptance are factors that could impact Daxor's trajectory. The current expansion trend showcases growth potential, but it’s essential to continuously monitor performance metrics and market reactions. Investors are encouraged to weigh Daxor's innovative capabilities against these risks to make informed decisions about their investment strategy in this promising yet volatile sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Expansion Leverages Daxor’s ezBVA Lab to Deliver 98% Accurate Diagnostics with Zero Capital Investment
Oak Ridge, TN, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, continues its strategic expansion into the outpatient cardiology market with the opening of a new BVA program at a leading healthcare facility in Southern Middle Tennessee. This integration brings Daxor’s state-of-the-art testing to a high-volume preventative care setting, driving clinical excellence in chronic disease management.
Utilizing Daxor’s proprietary, Tennessee-based ezBVA Lab workflow, the facility will benefit from a 24-hour turnaround time on comprehensive blood volume metrics, enabling rapid, data-driven clinical decisions for cardiology patients throughout the region.
“This milestone marks another significant step in our regional expansion and underscores the critical role of precise volume assessment in patient care," said Michael Feldschuh, Daxor CEO and President. "With 98% accuracy, our technology empowers clinicians to move beyond 'best guesses' to data-driven fluid management. By utilizing our ezBVA Lab service, clinicians can implement our gold-standard diagnostic into the outpatient setting, which has reimbursement codes with no capital investment. This can meaningfully contribute significantly to improving patient outcomes and reducing healthcare costs.”
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR) is tackling healthcare's "multi-billion-dollar silent crisis", the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor is proud to manufacture and distribute its patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic which offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion.
For more information, please visit our website at Daxor.com.
Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact
Bret Shapiro
COO – Head of Capital Markets
COREIR
516-222-2560
brets@coreir.com|www.coreir.com
FAQ**
How does Daxor Corporation DXR plan to utilize the new BVA program in Southern Middle Tennessee to expand its footprint in the outpatient cardiology market?
What are the expected benefits for healthcare facilities integrating Daxor Corporation DXR's ezBVA Lab service regarding patient outcomes and cost reduction?
As Daxor Corporation DXR expands, what strategies are in place to ensure clinician acceptance of its blood volume measurement technology and its integration into standard practices?
What risks should investors consider regarding Daxor Corporation DXR’s future market expansion and product commercialization efforts as stated in the recent release?
**MWN-AI FAQ is based on asking OpenAI questions about Daxor Corporation (NASDAQ: DXR).
NASDAQ: DXR
DXR Trading
1.18% G/L:
$11.61 Last:
445 Volume:
$11.61 Open:
